Donepezil- or rivastigmine-induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain

Drug Development Research

Volumn 68, Issue 5, 2007, Pages 253-260

  Gupta, Ramesh C ^a   Dekundy, Andrzej ^b  

^a MURRAY STATE UNIVERSITY   (United States)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Brain acetylcholinesterase; DFP; Donepezil; Neramexane; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; DONEPEZIL; DYFLOS; NERAMEXANE; RIVASTIGMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CORPUS STRIATUM; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; MALE; NONHUMAN; RAT;

EID: 36849023031     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20186     Document Type: Article

References (54)

1. Ballard CG. 2002. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 47:64-70.
2. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. 2002. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41:3555-3564.
3. Bartus RT, Dean RLI, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
4. Bullock R. 2006. Efficacy and safety of memantine in moderate-to-severe Alzheimer's disease: the evidence to date. Neurology 20:23-29.
5. Cacabelos R, Takeda M, Winblad B. 1999. The glutamatergic system and neurodegeneration in dementia: preventative strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14:3-47.
6. Corey-Bloom J, Anand R, Veach J. 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1:55-65.
7. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer's disease: a disorder of cortical neurons. Science 219:1184-1190.
8. Danysz W, Parsons CG. 2003. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18:S23-S32.
9. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. 2000. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicol Res 2:85-97.
10. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E. 2003. Kinetic properties of human acetylcholinesterase and butylylcholinesterase in the presence of drugs for Alzheimer's disease. Alzheimers Dis Assoc Disord 17:117-126.
11. Farlow MR, Evans RM. 1998. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51(Suppl 1):S36-S44.
12. Farlow MR, Anand R, Messina J Jr, Hartman R, Veach J. 2000. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44:236-241.
13. Farlow MR, Tariot PN, Grossberg GT, Gergel I, Graham S, Jin J. 2003. Memantine/donepezil dual therapy is superior to placebo/ donepezil therapy for treatment of moderate to severe Alzheimer's disease. Neurology 60(Suppl 1):S48.003.
14. Giacobini E, Spiegel R, Enz A, Verff AE, Cutler NR. 2002. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109:1053-1065.
15. Gollan TH, Salmon DP, Paxton JL. 2006. Word association in early Alzheimer's disease. Brain Language 99:289-303.
16. Greets H, Grossberg GT. 2006. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J Clin Pharmacol 46(Suppl 1):8S-16S.
17. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. 1997. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909-918.
18. Gupta RC, Dekundy A. 2005. Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies. Drug Develop Res 64:71-81.
19. Gupta RC, Milatovic D, Dettbarn W-D. 2000. Cholinergic and noncholinergic brain biomarkers of insecticide exposure and effects. Hum Exp Toxicol 19:297-308.
20. Gupta RC, Milatovic D, Dettbarn W-D. 2001a. Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: protection by antioxidants. Neurotoxicology 22:271-282.
21. Gupta RC, Milatovic D, Dettbarn W-D. 2001b. Nitric oxide modulates high-energy phosphates in brain regions of rats intoxicated with diisopropylphosphorofluoridate or carbofuran: prevention by N-tert-butyl- α-phenylnitrone or vitamin E. Arch Toxicol 75:346-356.
22. Gupta RC, Milatovic S, Dettbarn W-D, Aschner M, Milatovic D. 2007. Neuronal oxidative injury and dendritic damage induced by carbofuran: protection by memantine. Toxicol Appl Pharmacol 219:97-105.
23. Hartmann S, Möbius HJ. 2003. Tolerabiliry of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 18:81-85.
24. Hynd MR, Scott HL, Dodd PR. 2004. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45:583-595.
25. Ibach B, Haen E. 2004. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharmaceut Design 10:231-251.
26. Knopman D. 2003. Pharmacotherapy for Alzheimer's disease: 2002. Clin Neuropharmacol 26:93-101.
27. Lancelot E, Beal MF. 1998. Glutamate toxicity in chronic neurodegenerative disease. Progr Brain Res 116:331-347.
28. Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S. 1980. Changes in the monoamine-containing neurons of the human CNS in senile dementia. Br J Psychiatry 136:533-541.
29. Mathews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. 2002. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 51:407-416.
30. Murphy MF, Sramek JJ, Kurtz MM, et al. 1998. Optimizing the development of the next generation of compounds for Alzheimer's disease. Greenwich Medical Media Ltd: London.
31. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. 2000. Comparison of inhibitoiy activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase inhibitors in vitro. Methods Find Exp Clin Pharmacol 22:609-613.
32. Ott BR, Blake LM, Kagan E, Resnick M. 2007. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol 254:351-358.
33. Parihar MS, Brewer GJ. 2007. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 292:C8-C23.
34. Perry RJ, Hodges JR. 1999. Attention and executive deficits in Alzheimer's disease: a critical review. Brain 122:383-404.
35. Polinsky RJ. 1998. Clinical pharmacology of rivastigmine; a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20:634-647.
36. Raveh L, Chapman S, Cohen G, Alkalay D, Gilat E, Rabinovitz I, Weisman BA. 1999. The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology 20:551-560.
37. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341.
38. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. 2006. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49-54.
39. Reskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S. 2006. Memantine treatment in mild to moderate Alzheimer's disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704-715.
40. Seali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepu G. 2002. Effect of subchronic administration of metrifonate, rivastigmine, and donepezil on brain acetylcholine in aged F344 rats. J Neurotransm 109:7-8.
41. Schmitt FA, Van Dyck CH, Wichems CH, Olin JT. 2006. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil. An exploratory reanalysis. Alzheimer Dis Assoc Disord 20:255-262.
42. Seltzer B. 2006. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res 34:339-347.
43. Seltzer B. 2007. Donepezil: an update. Exp Opin Pharmacother 8:1011-1023.
44. Solberg Y, Belkin M. 1997. The role of excitotoxicity in organophosphorus nerve agent's central poisoning. Trends Pharmacol Sci 18:183-185.
45. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gurgel I. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291:317-324.
46. Weinstock M. 1999. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12:307-323.
47. Wengel SP, Roccaforte WH, Burke WJ, Bayer BL, McNeilly BP, Knop D. 1998. Behavioral complications associated with donepezil. Am J Psychiatry 155:1632-1633.
48. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomized controlled trial. Galantamine International-1 Study Group. BMJ 321:1445-1449.
49. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A-L, Zhang R, Haglund A, Subbiah P. 2001. A 1-year, randomized, placebo controlled study of donepezil in patients with mild to moderate AD. Neurology 57:489-495.
50. Winblad B, Möbius HJ, Stöffler A. 2002. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neurol Transm 62(Suppl):217-225.
51. Winblad B, Wimo A, Engedal K, et al. 2006. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geratr Cogn Disord 21:353-363.
52. Wirth Y, Winblad B, Jones RW, Stöffler A, Möbius HJ. 2006. Efficacy and safety of memantine in moderate to severe Alzheimer's disease - a meta-analysis. Alzheimer's Dementia 2:S365-S366.
53. Woolf NJ. 2006. Acetylcholine, cognition, and consciousness. J Mol Neurosci 30:219-222.
54. Wynn ZJ, Cummings JL. 2004. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 17:100-108.